These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31898040)

  • 21. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates.
    Gersin KS; Rothstein RI; Rosenthal RJ; Stefanidis D; Deal SE; Kuwada TS; Laycock W; Adrales G; Vassiliou M; Szomstein S; Heller S; Joyce AM; Heiss F; Nepomnayshy D
    Gastrointest Endosc; 2010 May; 71(6):976-82. PubMed ID: 20304396
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Beneficial Metabolic Effects of Duodenal Jejunal Bypass Liner for the Treatment of Adipose Patients with Type 2 Diabetes Mellitus: Analysis of Responders and Non-Responders.
    Stratmann B; Krepak Y; Schiffer E; Jarick I; Hauber M; Lee-Barkey YH; Fischer M; Tschoepe D
    Horm Metab Res; 2016 Sep; 48(10):630-637. PubMed ID: 27589345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of the Duodenal-Jejunal Bypass Liner on Glycemic Control in Patients With Type 2 Diabetes With Obesity: A Meta-analysis With Secondary Analysis on Weight Loss and Hormonal Changes.
    Jirapinyo P; Haas AV; Thompson CC
    Diabetes Care; 2018 May; 41(5):1106-1115. PubMed ID: 29678867
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Effectiveness and Safety of the Duodenal-Jejunal Bypass Liner (DJBL) for the Management of Obesity and Glycaemic Control: a Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Yvamoto EY; de Moura DTH; Proença IM; do Monte Junior ES; Ribeiro IB; Ribas PHBV; Hemerly MC; de Oliveira VL; Sánchez-Luna SA; Bernardo WM; de Moura EGH
    Obes Surg; 2023 Feb; 33(2):585-599. PubMed ID: 36508156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Relevant Weight Reduction and Reversed Metabolic Co-morbidities Can Be Achieved by Duodenojejunal Bypass Liner in Adolescents with Morbid Obesity.
    Homan M; Kovač J; Orel R; Battelino T; Kotnik P
    Obes Surg; 2020 Mar; 30(3):1001-1010. PubMed ID: 31758471
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sustained weight loss after duodenal-jejunal bypass liner treatment in patients with body mass index below, but not above 35 kg/m
    Boonchaya-Anant P; Bueter M; Gubler C; Gerber PA
    Clin Obes; 2023 Feb; 13(1):e12561. PubMed ID: 36239531
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline glycated hemoglobin levels are associated with duodenal-jejunal bypass liner-induced weight loss in obese patients.
    Muñoz R; Dominguez A; Muñoz F; Muñoz C; Slako M; Turiel D; Pimentel F; Sharp A; Escalona A
    Surg Endosc; 2014 Apr; 28(4):1056-62. PubMed ID: 24196558
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is Early Reimplantation of the Duodenal-Jejunal Bypass Liner Viable?
    Leventi E; Günthert SJ; Stier C; Staikov P; Stein J; Farrag K
    Obes Surg; 2019 May; 29(5):1690-1693. PubMed ID: 30826914
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Acute pancreatitis as an adverse event in patients with the duodenal-jejunal bypass liner.
    Betzel B; Homan J; Aarts E; Janssen I; Spanier M; Wahab P; Groenen M; Berends F
    Endoscopy; 2015 Nov; 47(11):1050-3. PubMed ID: 26021308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Measures of glucose homeostasis during and after duodenal exclusion using a duodenal-jejunal bypass liner in a normoglycemic, nonobese canine model.
    Paszkiewicz RL; Burch MA; Asare Bediako I; Mkrtchyan H; Piccinini F; Ader M; Bresee C; Bergman RN
    Surg Obes Relat Dis; 2022 Jun; 18(6):694-702. PubMed ID: 35361540
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of the EndoBarrier Device: a 4-Year Follow-up of a Multicenter Randomized Clinical Trial.
    van Rijn S; Roebroek YGM; de Jonge C; Greve JWM; Bouvy ND
    Obes Surg; 2019 Apr; 29(4):1117-1121. PubMed ID: 30627989
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term effects of proximal small bowel exclusion by duodenal-jejunal bypass liner on weight reduction and glycemic control in diabetic patients.
    Deutsch L; Ben Haim L; Sofer Y; Gluck N; Santo E; Fishman S
    Surg Obes Relat Dis; 2018 Oct; 14(10):1561-1569. PubMed ID: 30449512
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure.
    Hollenbach M; Prettin C; Gundling F; Schepp W; Seufert J; Stein J; Rösch T; Aberle J; Feisthammel J; Petroff D; Hoffmeister A
    BMC Gastroenterol; 2018 Jul; 18(1):118. PubMed ID: 30021518
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Six months of treatment with the endoscopic duodenal-jejunal bypass liner does not lead to decreased systemic inflammation in obese patients with type 2 diabetes.
    de Jonge C; Rensen SS; D'Agnolo HM; Bouvy ND; Buurman WA; Greve JW
    Obes Surg; 2014 Feb; 24(2):337-41. PubMed ID: 24357127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner.
    de Moura EG; Martins BC; Lopes GS; Orso IR; de Oliveira SL; Galvão Neto MP; Santo MA; Sakai P; Ramos AC; Garrido Júnior AB; Mancini MC; Halpern A; Cecconello I
    Diabetes Technol Ther; 2012 Feb; 14(2):183-9. PubMed ID: 21932999
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and Effectiveness of an Endoscopically Placed Duodenal-Jejunal Bypass Device (EndoBarrier®): Outcomes in 114 Patients.
    Forner PM; Ramacciotti T; Farey JE; Lord RV
    Obes Surg; 2017 Dec; 27(12):3306-3313. PubMed ID: 29018990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of Duodenal-Jejunal Bypass Liner (EndoBarrier®) on Gastric Emptying in Obese and Type 2 Diabetic Patients.
    de Moura EG; Lopes GS; Martins BC; Orso IR; Coutinho AM; de Oliveira SL; Sakai P; Galvão-Neto Mdos P; Santo MA; Sapienza MT; Cecconello I; Buchpiguel CA
    Obes Surg; 2015 Sep; 25(9):1618-25. PubMed ID: 25691349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse Events of the Duodenal-Jejunal Bypass Liner: a Systematic Review.
    Betzel B; Drenth JPH; Siersema PD
    Obes Surg; 2018 Nov; 28(11):3669-3677. PubMed ID: 30121857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes.
    Rodriguez L; Reyes E; Fagalde P; Oltra MS; Saba J; Aylwin CG; Prieto C; Ramos A; Galvao M; Gersin KS; Sorli C
    Diabetes Technol Ther; 2009 Nov; 11(11):725-32. PubMed ID: 19905889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The duodenal-jejunal bypass liner for the treatment of type 2 diabetes mellitus and/or obesity: a systematic review.
    Zechmeister-Koss I; Huić M; Fischer S;
    Obes Surg; 2014 Feb; 24(2):310-23. PubMed ID: 24293185
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.